Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T12:00:56.938Z.
Calculation as of: 2026-10-06T12:00:56.938Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 026981202cadb8e73b6cbd63f18abfa8ffa74fea80ac6bbb32512047e0825b9f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$2.64B
EV/Sales Ratio
17.10x
TTM Avg
29.76x
3Y Avg
20.24x
5Y Avg
5044.79x
Market Cap
$2.69B
EV/Sales Ratio
1.51x
TTM Avg
1.36x
3Y Avg
1.94x
5Y Avg
2.46x
Market Cap
$2.69B
EV/Sales Ratio
1.58x
TTM Avg
1.35x
3Y Avg
1.18x
5Y Avg
1.10x
Market Cap
$2.51B
EV/Sales Ratio
36.90x
TTM Avg
23.51x
3Y Avg
28.15x
5Y Avg
52.69x
Market Cap
$2.43B
EV/Sales Ratio
0.90x
TTM Avg
0.75x
3Y Avg
0.67x
5Y Avg
0.62x
Market Cap
$2.87B
EV/Sales Ratio
4.88x
TTM Avg
7.37x
3Y Avg
10.06x
5Y Avg
14.84x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.64B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | 17.10x | 29.76x | 20.24x | 5044.79x |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 1.51x | 1.36x | 1.94x | 2.46x |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 1.58x | 1.35x | 1.18x | 1.10x |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.51B | 36.90x | 23.51x | 28.15x | 52.69x |
| Clover Health Investments, Corp. (CLOV)vs › | $2.43B | 0.90x | 0.75x | 0.67x | 0.62x |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 4.86x | 3.13x | 3.31x | 5.18x |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 4.88x | 7.37x | 10.06x | 14.84x |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | 4.71x | 6.25x | 8.23x | 6.93x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
